Our ability to allow the patient to remain on standard of care therapy has two important consequences: 1) they are less likely to experience systemic tumor progression due to treatment interruption, and 2) the presence of trastuzumab will block systemically expressed Her2, making it less likely for the bridging protein to bind to any normal tissues expressing Her2. Here, ERBB2 is linked to neoplasm.